Sivelestat Lowers Sepsis-ARDS Mortality in Small, East Asian Studies
This etiologically strict meta-analysis tests whether neutrophil elastase inhibition lowers mortality in sepsis-induced acute respiratory distress syndrome, but the evidence base is small, regional, and open to confounding by co-interventions.
📅 Journal publication: 2026(online Oct 27, 2026)·Last updated: Nov 15, 2026
Sivelestat may lower mortality in sepsis-induced ARDS.
Sepsis-induced acute respiratory distress syndrome (ARDS) has high mortality, and therapies like sivelestat could improve outcomes. Sivelestat reduced mortality in sepsis-induced ARDS (OR=0.55, 95% CI 0.36-0.84) in a meta-analysis of 10 studies. While sivelestat shows promise in reducing mortality, evidence is not yet sufficient to guide phenotype-based prescribing. Reliance on co-intervention discrepancies limits applicability. Sivelestat may reduce mortality in sepsis-induced ARDS, but evidence lacks clarity for guided usage.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Free account, no credit card. Includes 1 full deep analysis every month.
Authors:Haibier A, Ma J, Wang Y, Wu T
Citation:Haibier A, Ma J, Wang Y, et al. Efficacy and safety of sivelestat in sepsis-induced acute respiratory distress syndrome: an updated meta-analysis based on disease severity and treatment strategy subgroups. Frontiers in medicine. 2026;13:1986111. doi:10.3389/fmed.2026.1986111